Topline data announced from Phase II BLAZE 4 study of bamlanivimab, VIR 7831 (GSK 4182136) which reduced viral load by 70% in COVID 19 patients. Eli Lilly/GSK/Vir Biotech
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest